Vimarsana
Biggest News Aggregation in the World

Page 3 - Marks Shearman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marks Shearman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marks Shearman Today - Breaking & Trending Today

Editas Medicine Reports Preclinical Data Demonstrating - Vimarsana News

Editas Medicine Reports Preclinical Data Demonstrating

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a...

EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today - Vimarsana News

EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today

After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.

Editas Medicine Announces First Quarter 2021 Results and - Vimarsana News

Editas Medicine Announces First Quarter 2021 Results and

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicine...

Editas Medicine Announces First Quarter 2021 Results and Update - Vimarsana News

Editas Medicine Announces First Quarter 2021 Results and Update

Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing nov...

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief - Vimarsana News

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer May 05, 2021 06:59 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development f...